Dopamine beta hydroxylase

Jump to: navigation, search
dopamine beta-hydroxylase (dopamine beta-monooxygenase)
Identifiers
SymbolDBH
Entrez1621
HUGO2689
OMIM609312
RefSeqNM_000787
UniProtP09172
Other data
EC number1.14.17.1
LocusChr. 9 q34

Dopamine β-hydroxylase (DBH) is an enzyme that converts dopamine to norepinephrine:

DBH is a 290 kDa copper-containing oxygenase consisting of four identical subunits, and its activity requires ascorbate as a cofactor. [1] It is the only enzyme involved in the synthesis of small-molecule neurotransmitters that is membrane-bound, making norepinephrine and epinephrine the only transmitters synthesized inside vesicles. It is expressed in noredrenergic nerve terminals of the central and peripheral nervous systems, as well as in chromaffin cells of the adrenal medulla.

DBH is inhibited by disulfiram, [2] tropolone, [3] and, most selectively, by nepicastat. [4]

See also

References

  1. Rush RA, Geffen LB (1980). "Dopamine beta-hydroxylase in health and disease". Crit Rev Clin Lab Sci. 12 (3): 241–77. PMID 6998654.
  2. Goldstein M, Anagnoste B, Lauber E, McKeregham MR (1964). "Inhibition of dopamine-beta-hydroxylase by Disulfiram". Life Sci. 3: 763–7. PMID 14203977.
  3. Goldstein M, Lauber E, McKeregham MR (1964). "Inhibition of dopamine-beta-hydroxylase by tropolone and other chelating agents". Biochem Pharmacol. 13: 1103–6. PMID 14201135.
  4. Stanley WC et. al. (1997). "Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase". 121 (8): 1803–9. PMID 9283721. Text "journal+ Br J Pharmacol " ignored (help)

External links


Linked-in.jpg